Has Mary Huntsinger received payments from drug or device companies?

Yes. Drug and device makers reported $11,921 in general payments to Mary Huntsinger across 158 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Mary Huntsinger did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Mary Huntsinger come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Mary Huntsinger

Acute Care · Los Angeles, CANPI 1285674960

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $7,763 of the $11,921 with a category attached, or 65.1%. Boston Scientific accounts for 61.1% of it on its own, with 13 other manufacturers making up the rest. 2025 is the largest year on record at $4,581, 7.6 times the $603 reported in 2021. Among acute care clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$11,921in general payments, 2019–2025

Across 158 payments — averaging $75.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boston Scientific$7K
Cvrx, Inc.$2K
Abbott$976
Novartis$404
Irhythm Technologies, Inc.$358
ZOLL Respicardia, Inc.$189
plus $707 from 8 others

What the payments were for

Travel & lodging$4,15735%
Food & beverage$7,76365%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boston Scientific	90	$7,282
Cvrx, Inc.	16	$2,004
Abbott	14	$976
Novartis	16	$404
Irhythm Technologies, Inc.	3	$358
ZOLL Respicardia, Inc.	2	$189
Kestra Medical Technology Services, Inc.	5	$176
Impulse Dynamics (USA) Inc.	1	$145
E.r. Squibb & Sons, L.L.C.	1	$125
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	4	$90
Biotronik Inc.	2	$88
Pfizer	2	$34
Lantheus Medical Imaging, Inc.	1	$26
Cardiva Medical, Inc.	1	$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

GENERAL - THERAPIES$2,351
Barostim Neo System$1,201
WATCHMAN Access System$619
ZIO XT Patch$358
OPTIMIZER$291
LEQVIO$270
QUADRA ASSURA$181
remede System$173
THORATEC HEARTMATE 3 LVAS IMPLANT KIT$164
ASSURITY$146
GENERAL PAIN MANAGEMENT$145
WATCHMAN FLX$129
ELIQUIS$125
LUX-Dx Insertable Cardiac Monitor$118
EMBLEM MRI S-ICD$114
BodyGuardian$108

How this compares

$11,921 in reported general payments places this provider in the 95th percentile of 1,153 acute care providers in California.

See all acute care providers in California →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	29	$24,476

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
PfizerEliquis	$34	$24,47629 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,153 acute care providers in California.

Other acute care in Los Angeles

Frances DyLos Angeles$57K
Kori Ann JohnstonLos Angeles$42K
Sunita BoparaiLos Angeles$37K
Sherona BauLos Angeles$32K
Stacey GrossLos Angeles$22K
Charlotte LipskyLos Angeles$10K
Kimberly TranLos Angeles$8K
Lisa YenLos Angeles$7K
Rafael BegluyanLos Angeles$7K
Margo MinissianLos Angeles$7K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →